Lexeo Therapeutics Appoints Narinder Bhalla as Chief Medical Officer

Lexeo Therapeutics has announced the appointment of Narinder Bhalla, MD, as its new Chief Medical Officer. Dr. Bhalla brings extensive experience in clinical development and medical affairs to the gene therapy company.

Prior to joining Lexeo Therapeutics, Dr. Bhalla served as Senior Vice President and Head of Global Medical Affairs at Bristol Myers Squibb. In this role, he oversaw the company’s medical strategies and initiatives worldwide.

This appointment comes as Lexeo Therapeutics continues to advance its pipeline of gene therapies for neurological disorders. The company aims to develop and commercialize innovative treatments for patients with meaningful unmet medical needs.

Readers can find more details about this appointment and other industry moves in the full story on STAT+.